ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.

Bibliographic Details
Main Authors:	Kwekkeboom, D, Krenning, E, Scheidhauer, K, Lewington, V, Lebtahi, R, Grossman, A, Vitek, P, Sundin, A, Plöckinger, U
Format:	Conference item
Published:	2009

Similar Items

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers.
by: O'Toole, D, et al.
Published: (2009)

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation.
by: Arnold, R, et al.
Published: (2009)

ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors.
by: Pavel, M, et al.
Published: (2010)

ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas.
by: Pape, U, et al.
Published: (2012)

Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA pentetreotide.
by: Isidori, A, et al.
Published: (2002)

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
by: Kaltsas, G, et al.
Published: (2005)

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
by: Kaltsas, G, et al.
Published: (2001)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
by: Ur, E, et al.
Published: (1993)

Multimodality palliative treatment of (111)In-pentetreotide negative/(123)I-MIBG positive metastatic carcinoid - a case report.
by: Dworakowska, D, et al.
Published: (2008)

Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide.
by: Kaltsas, G, et al.
Published: (1998)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.
by: Cakir, M, et al.
Published: (2010)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications.
by: Cakir, M, et al.
Published: (2010)

Gastroenteropancreatic neuroendocrine tumours.
by: Modlin, I, et al.
Published: (2008)

The diagnosis and medical management of advanced neuroendocrine tumors.
by: Kaltsas, G, et al.
Published: (2004)

Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
by: King, C, et al.
Published: (1993)

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
by: Chan, H, et al.
Published: (2010)

Vasculopathic changes, a somatostatin-producing neuroendocrine carcinoma and a jejunal gastrointestinal stromal tumor in a patient with type 1 neurofibromatosis.
by: Chetty, R, et al.
Published: (2009)

A comparison of diagnostic and management pathways for patients with nung neuroendocrine tumors in ENETS Centres of Excellence vs non-accredited centres in the UK: Results from the National Lung NET pathway Project (‘LEAP’)
by: Talbot, D, et al.
Published: (2018)

Intraductal pancreatic neuroendocrine tumor.
by: Chetty, R, et al.
Published: (2009)

Ductules in pancreatic neuroendocrine tumors.
by: Chetty, R, et al.
Published: (2004)

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).
by: Ramage, J, et al.
Published: (2012)

Targeted radionuclide therapy for neuroendocrine tumours: principles and application.
by: Druce, MR, et al.
Published: (2010)

Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.
by: Klimstra, D, et al.
Published: (2010)

Neuroendocrine immune responses to inflammation: the concept of the neuroendocrine immune loop.
by: Chikanza, I, et al.
Published: (1996)

Update on neuroendocrine tumours
by: Grossman, AB
Published: (2012)

The potential role of D(2) dopamine receptors as a target in the management of neuroendocrine tumors.
by: Ribeiro-Oliveira, A, et al.
Published: (2008)

Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy
by: Evans, JS, et al.
Published: (2022)

Evaluation of the Association between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
by: Den Gupta, P, et al.
Published: (2011)

An FGFR4 polymorphism is implicated in the progression of neuroendocrine tumors
by: Serra, S, et al.
Published: (2009)

Brain opiates and neuroendocrine function.
by: Grossman, A
Published: (1983)

Aripiprazole in schizophrenia: consensus guidelines.
by: Travis, M, et al.
Published: (2005)

Glucose-induced changes in somatostatin-14 and somatostatin-28 released from rat hypothalamic fragments 'in vitro'.
by: Lengyel, A, et al.
Published: (1984)

Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
by: Korbonits, M, et al.
Published: (1998)

Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors
by: Lines, K, et al.
Published: (2017)

Neuroendocrine tumours: a hope and a prayer.
by: Grossman, A
Published: (2009)

Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors: New Therapeutic Approaches
by: Stevenson, M, et al.
Published: (2018)

Functional and biocompatible polymeric nanopatricels for targetted PET imaging of neuroendocrine tumors.
by: Singh Medha.
Published: (2013)

A scintigraphic comparison of iodine-123-metaiodobenzylguanidine and an iodine-labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumors.
by: Bomanji, J, et al.
Published: (1992)